These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 16628715)

  • 41. Lenalidomide in combination with dexamethasone for the treatment of multiple myeloma after one prior therapy.
    Hazarika M; Rock E; Williams G; Dagher R; Sridhara R; Booth B; Farrell A; Justice R; Pazdur R
    Oncologist; 2008 Oct; 13(10):1120-7. PubMed ID: 18922829
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bisphosphonates--role in cancer therapies.
    Mehrotra B
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):19-26. PubMed ID: 19371811
    [No Abstract]   [Full Text] [Related]  

  • 43. Myeloma and the newly diagnosed patient: a focus on treatment and management.
    Rajkumar SV; Kyle RA; Gertz MA
    Semin Oncol; 2002 Dec; 29(6 Suppl 17):5-10. PubMed ID: 12520478
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cutaneous involvement in multiple myeloma and bortezomib.
    Siniscalchi A; Fratoni S; Santeusanio G; Del Poeta G; de Fabritiis P; Caravita T
    Ann Hematol; 2009 Nov; 88(11):1137-9. PubMed ID: 19259673
    [No Abstract]   [Full Text] [Related]  

  • 45. Kappa light chain myeloma with initial cutaneous involvement.
    Saka B; Erten N; Oztürk G; Yilmaz C; Dogan O; Buyukbabani N; Besisik SK
    Ann Hematol; 2006 Apr; 85(4):272-4. PubMed ID: 16425024
    [No Abstract]   [Full Text] [Related]  

  • 46. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma.
    Lokhorst HM; Schmidt-Wolf I; Sonneveld P; van der Holt B; Martin H; Barge R; Bertsch U; Schlenzka J; Bos GM; Croockewit S; Zweegman S; Breitkreutz I; Joosten P; Scheid C; van Marwijk-Kooy M; Salwender HJ; van Oers MH; Schaafsma R; Naumann R; Sinnige H; Blau I; Delforge M; de Weerdt O; Wijermans P; Wittebol S; Duersen U; Vellenga E; Goldschmidt H; ;
    Haematologica; 2008 Jan; 93(1):124-7. PubMed ID: 18166796
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
    Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
    Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Deep vein thrombosis and pulmonary embolism in a patient with multiple myeloma treated with thalidomide and dexamethasone].
    Miyazawa Y; Irisawa H; Uchiumi H; Saitoh T; Handa H; Matsushima T; Tsukamoto N; Karasawa M; Murakami H; Nojima Y
    Rinsho Ketsueki; 2006 Jul; 47(7):656-60. PubMed ID: 16910577
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma.
    Ciolli S; Leoni F; Casini C; Breschi C; Santini V; Bosi A
    Br J Haematol; 2008 Jun; 141(6):814-9. PubMed ID: 18410447
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study.
    Offidani M; Corvatta L; Polloni C; Piersantelli MN; Gentili S; Galieni P; Visani G; Alesiani F; Catarini M; Brunori M; Samori A; Burattini M; Centurioni R; Ferranti M; Giuliodori L; Candela M; Mele A; Marconi M; Leoni P
    Br J Haematol; 2009 Mar; 144(5):653-9. PubMed ID: 19036082
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Guideline for the appropriate use of thalidomide in the treatment of multiple myeloma].
    Rinsho Ketsueki; 2005 Jan; 46(1):22-42. PubMed ID: 16724412
    [No Abstract]   [Full Text] [Related]  

  • 52. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
    Palumbo A; Bringhen S; Falco P; Cavallo F; Ambrosini MT; Avonto I; Gay F; Caravita T; Bruno B; Boccadoro M
    Cancer; 2007 Aug; 110(4):824-9. PubMed ID: 17594696
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Metastatic bone disease and the role of bisphosphonates.
    Ellis MJ
    Br J Hosp Med; 1996 Oct 2-15; 56(7):339-45. PubMed ID: 8899222
    [No Abstract]   [Full Text] [Related]  

  • 54. Thalidomide and dexamethasone for newly diagnosed multiple myeloma: is this really the standard of care?
    Nabhan C; Bitran JD
    J Clin Oncol; 2006 Jun; 24(18):2967-8; author reply 2968-9. PubMed ID: 16782938
    [No Abstract]   [Full Text] [Related]  

  • 55. Current treatment for multiple myeloma.
    Avigan D; Rosenblatt J
    N Engl J Med; 2014 Sep; 371(10):961-2. PubMed ID: 25184869
    [No Abstract]   [Full Text] [Related]  

  • 56. Multiple myeloma presenting as eosinophilic pleural effusion.
    Mehta AA; Venkatakrishnan R; Jose W; Palaniappan M; Pavithran K
    Asia Pac J Clin Oncol; 2010 Dec; 6(4):256-9. PubMed ID: 21114774
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Frontline treatment of multiple myeloma in elderly patients.
    Moreau P; Hulin C; Facon T
    Blood Rev; 2008 Nov; 22(6):303-9. PubMed ID: 18550234
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Isatuximab: First Approval.
    Dhillon S
    Drugs; 2020 Jun; 80(9):905-912. PubMed ID: 32347476
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Development of multiple myeloma in a case of longstanding ankylosing spondylitis: more than a coincidence?
    Kumar S; Gnanapandithan K; Sharma A; Malhotra P; Singh S; Varma S
    Int J Rheum Dis; 2011 Feb; 14(1):e12-3. PubMed ID: 21303471
    [No Abstract]   [Full Text] [Related]  

  • 60. Thalidomide and lenalidomide in multiple myeloma.
    Mazumder A; Jagannath S
    Best Pract Res Clin Haematol; 2006; 19(4):769-80. PubMed ID: 16997182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.